Close Menu

NEW YORK – The US Food and Drug Administration has approved GlaxoSmithKline's PARP inhibitor niraparib (Zejula) as a first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of their biomarker status.

Less than 50 percent of women with advanced ovarian cancer live for five years. "This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend the time it takes for their cancer to progress," GSK CSO Hal Barron said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.